Navigation Links
Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
Date:10/14/2008

BOSTON, Oct. 14 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (OTC Pink Sheets: SNDY) is pleased to announce that the Company is in the final stages to upgrade its status on the Pinksheets Electronic OTC Markets from Limited Information to Current Information. The Company is in the process of completing their Issuer Information Statement, which will be accompanied by an attorney's opinion letter. The Company expects to have its status upgraded by the end of the quarter.

A Pinksheets status of current information indicates that Solos Endoscopy, Inc. will make its current information publicly available through the OTC Disclosure and News Service according to the Pink OTC Markets manual: Guidelines for Providing Adequate Current Information. There are currently 1,111 companies trading under current information as opposed to 521 companies trading under limited information. The 1,111 companies trading under current information represented approximately 65.4% of the total dollar volume traded during the month of December 2007, according to Pinksheets.com.

"By upgrading our status to current information, we are demonstrating to our shareholders that we are working hard to increase the value of our stock as we move forward with our business strategy over the next several months," stated Bob Segersten, President of Solos Endoscopy, Inc.

Please click on the link to view the Guidelines for Providing Adequate Current Information. (http://www.pinksheets.com/content/doc/ps/Disclosure/Guidelines/2.pdf)

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: http://www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
2. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
3. Essilor Finalizes Satisloh Agreement
4. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
5. 2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced
6. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. Prix Galien USA Announces 2008 Final Candidates
9. White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product
10. Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
11. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... and diminished effectiveness over time. A recent study published in STEM CELLS suggests ... stimulating subventricular zone (SVZ) stem cells to produce more neural cells. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... Executive search firm, Slone Partners, ... Services. Harvill is a distinguished life sciences expert with a proven track record ... in a wide range of services related to laboratory testing and analysis for ...
(Date:3/27/2017)... 2017 Infectex Ltd., a Russian portfolio company of Maxwell Biotech ... SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... ( USA ) and the US National Institutes of Health. ... ... Fund Logo ...
(Date:3/27/2017)... Cambridge, MA (PRWEB) , ... March 27, 2017 ... ... published a method to engineer scalable and customizable vascular grafts in JoVE’s Video ... that may lead to new and improved ways of treating coronary artery disease ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market ... the next decade to reach approximately $14.21 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited ... to the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... the largest German biometrics company the two government leaders could see the ... well as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
(Date:3/9/2017)... , Australia , March 9, 2017 ... data at the prestigious World Lung Imaging Workshop at ... Andreas Fouras , was invited to deliver the latest ... medicine. This globally recognised event brings together leaders at ... the latest developments in lung imaging. ...
Breaking Biology News(10 mins):